☰

Jeffrey D. Kearns, Ph.D. - Publications

Affiliations: 
Chemistry University of California, San Diego, La Jolla, CA 
Area:
signaling, transcription, computational network; stress and immune responses, apoptosis, proliferation
Tree Info Similar researchers PubMed Report error

26 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Casaletto JB, Geddie ML, Abu-Yousif AO, Masson K, Fulgham A, Boudot A, Maiwald T, Kearns JD, Kohli N, Su S, Razlog M, Raue A, Kalra A, Håkansson M, Logan DT, et al. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM. Proceedings of the National Academy of Sciences of the United States of America. PMID 30898885 DOI: 10.1073/Pnas.1819085116  0.381
2016 Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science Translational Medicine. 8: 324ra14. PMID 26843189 DOI: 10.1126/Scitranslmed.Aad5640  0.313
2016 Harb WA, Adjei AA, Beeram M, Pipas JM, Chen S, Valencia A, Rimkunas V, McClure T, Kearns JD, Nering R, Lieu CH. Final results of a first-in-human study evaluating the safety, pharmacology and initial efficacy of MM-151, an oligoclonal anti-EGFR antibody in patients with refractory solid tumors. Journal of Clinical Oncology. 34: 2518-2518. DOI: 10.1200/Jco.2016.34.15_Suppl.2518  0.335
2016 Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei A, Montagut C, Nicolantonio FD, Nering R, Bardelli A. Abstract B33: The oligoclonal antibody MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-B33  0.313
2015 Tsui R, Kearns JD, Lynch C, Vu D, Ngo KA, Basak S, Ghosh G, Hoffmann A. IκBβ enhances the generation of the low-affinity NFκB/RelA homodimer. Nature Communications. 6: 7068. PMID 25946967 DOI: 10.1038/Ncomms8068  0.723
2015 Kearns JD, Bukhalid R, Sevecka M, Tan G, Gerami-Moayed N, Werner SL, Kohli N, Burenkova O, Sloss CM, King AM, Fitzgerald JB, Nielsen UB, Wolf BB. Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic. Molecular Cancer Therapeutics. 14: 1625-36. PMID 25911688 DOI: 10.1158/1535-7163.Mct-14-0772  0.661
2015 Lieu CH, Beeram M, Harb WA, Kearns JD, Sloss CM, Nering R, Adjei AA, Wolf BB. Safety, pharmacology, and preliminary clinical activity of MM-151: An oligocolnal anti-EGFR theraputic in patients with cetuximab-resistant CRC and other refractory solid tumors. Journal of Clinical Oncology. 33: 647-647. DOI: 10.1200/Jco.2015.33.3_Suppl.647  0.303
2015 Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Nicolantonio FD, Nering R, Bardelli A. Abstract LB-B05: MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancer cells harboring EGFR extracellular domain mutations Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-B05  0.321
2014 Lieu CH, Harb WA, Beeram M, Power L, Kearns JD, Nering R, Moyo VM, Wolf BB, Adjei AA. Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors. Journal of Clinical Oncology. 32: 2518-2518. DOI: 10.1200/Jco.2014.32.15_Suppl.2518  0.362
2013 Longo DM, Selimkhanov J, Kearns JD, Hasty J, Hoffmann A, Tsimring LS. Dual delayed feedback provides sensitivity and robustness to the NF-κB signaling module. Plos Computational Biology. 9: e1003112. PMID 23825938 DOI: 10.1371/Journal.Pcbi.1003112  0.62
2012 Shih VF, Davis-Turak J, Macal M, Huang JQ, Ponomarenko J, Kearns JD, Yu T, Fagerlund R, Asagiri M, Zuniga EI, Hoffmann A. Control of RelB during dendritic cell activation integrates canonical and noncanonical NF-κB pathways. Nature Immunology. 13: 1162-70. PMID 23086447 DOI: 10.1038/Ni.2446  0.581
2012 Harms BD, Kearns JD, Su SV, Kohli N, Nielsen UB, Schoeberl B. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Methods in Enzymology. 502: 67-87. PMID 22208982 DOI: 10.1016/B978-0-12-416039-2.00004-5  0.301
2011 Wuerzberger-Davis SM, Chen Y, Yang DT, Kearns JD, Bates PW, Lynch C, Ladell NC, Yu M, Podd A, Zeng H, Huang TT, Wen R, Hoffmann A, Wang D, Miyamoto S. Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation. Immunity. 34: 188-200. PMID 21333553 DOI: 10.1016/J.Immuni.2011.01.014  0.524
2011 Tan G, Kearns JD, Gerami-Moayed N, Kohli N, Werner SL, King AM, Sloss CM, Bukhalid R, Nielsen UB. Abstract A210: Mechanism of action of MM-151, a potent mixture of three human antibody antagonists targeting EGFR. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A210  0.655
2011 Werner SL, Tan G, Kearns JD, King AM, Sloss C, Gerami-Moayed N, Bukhalid R, Nielsen UB. Abstract A144: Therapeutically targeting high-affinity ligand activation of EGFR with MM-151, an oligoclonal therapeutic. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-A144  0.651
2011 Wuerzberger-Davis SM, Chen Y, Yang DT, Kearns JD, Bates PW, Lynch C, Ladell NC, Yu M, Podd A, Zeng H, Huang TT, Wen R, Hoffmann A, Wang D, Miyamoto S. Nuclear export of the NF-κB inhibitor IκBα is required for proper B cell and secondary lymphoid tissue formation Immunity. 34: 449. DOI: 10.1016/j.immuni.2011.03.001  0.485
2009 Shih VF, Kearns JD, Basak S, Savinova OV, Ghosh G, Hoffmann A. Kinetic control of negative feedback regulators of NF-kappaB/RelA determines their pathogen- and cytokine-receptor signaling specificity. Proceedings of the National Academy of Sciences of the United States of America. 106: 9619-24. PMID 19487661 DOI: 10.1073/Pnas.0812367106  0.644
2009 Kearns JD, Hoffmann A. Integrating computational and biochemical studies to explore mechanisms in NF-{kappa}B signaling. The Journal of Biological Chemistry. 284: 5439-43. PMID 18940809 DOI: 10.1074/Jbc.R800008200  0.545
2008 Werner SL, Kearns JD, Zadorozhnaya V, Lynch C, O'Dea E, Boldin MP, Ma A, Baltimore D, Hoffmann A. Encoding NF-kappaB temporal control in response to TNF: distinct roles for the negative regulators IkappaBalpha and A20. Genes & Development. 22: 2093-101. PMID 18676814 DOI: 10.1101/Gad.1680708  0.744
2008 O'Dea EL, Kearns JD, Hoffmann A. UV as an amplifier rather than inducer of NF-kappaB activity. Molecular Cell. 30: 632-41. PMID 18538661 DOI: 10.1016/J.Molcel.2008.03.017  0.625
2008 Fusco AJ, Savinova OV, Talwar R, Kearns JD, Hoffmann A, Ghosh G. Stabilization of RelB requires multidomain interactions with p100/p52. The Journal of Biological Chemistry. 283: 12324-32. PMID 18321863 DOI: 10.1074/Jbc.M707898200  0.464
2007 O'Dea EL, Barken D, Peralta RQ, Tran KT, Werner SL, Kearns JD, Levchenko A, Hoffmann A. A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity. Molecular Systems Biology. 3: 111. PMID 17486138 DOI: 10.1038/Msb4100148  0.744
2007 Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. A fourth IkappaB protein within the NF-kappaB signaling module. Cell. 128: 369-81. PMID 17254973 DOI: 10.1016/J.Cell.2006.12.033  0.758
2006 Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IkappaBepsilon provides negative feedback to control NF-kappaB oscillations, signaling dynamics, and inflammatory gene expression. The Journal of Cell Biology. 173: 659-64. PMID 16735576 DOI: 10.1083/Jcb.200510155  0.761
2006 Kearns JD, Basak S, Werner SL, Huang CS, Hoffmann A. IκBε provides negative feedback to control NF-κB oscillations, signaling dynamics, and inflammatory gene expression Journal of Experimental Medicine. 203: i18-i18. DOI: 10.1084/JEM2036OIA18  0.693
2005 Barken D, Wang CJ, Kearns J, Cheong R, Hoffmann A, Levchenko A. Comment on "Oscillations in NF-kappaB signaling control the dynamics of gene expression". Science (New York, N.Y.). 308: 52; author reply 52. PMID 15802586 DOI: 10.1126/Science.1107904  0.734
Show low-probability matches.